Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma

Yamanouchi,Ryota; Harada,Koji; Ferdous,Tarannum; Ueyama,Yoshiya

doi:10.3892/mco.2018.1548

Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma

Authors:
- Ryota Yamanouchi
- Koji Harada
- Tarannum Ferdous
- Yoshiya Ueyama
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755‑8505, Japan
Published online on: January 10, 2018 https://doi.org/10.3892/mco.2018.1548
Pages: 400-406
Copyright: © Yamanouchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carbonyl reductase 1 (CBR1) is an enzyme that catalyzes the reduction of numerous compounds by using NADPH-dependent oxidoreductase activity. Decreased expression of CBR1 is associated with disease progression and an unfavorable outcome in several types of malignancies. The purpose of the current study was to determine whether CBR1 expression could be a useful prognostic factor in patients with oral squamous cell carcinoma (OSCC). Therefore, its mechanisms of action were investigated in order to understand how CBR1 affects cancer cell behavior in vitro. CBR1 expression was evaluated using immunohistochemistry and tissue samples obtained from 90 patients with OSCC. The associations between CBR1 expression, clinicopathological characteristics and patient survival were also analyzed. In addition, the role of CBR1 in cancer cell invasion and metastasis was examined, along with its underlying molecular mechanisms, via transfecting CBR1‑siRNA into the HSC2 human OSCC cell line. Immunohistochemical analysis revealed that biopsy tissue samples of 71.1% of the patients with OSCC were positive for CBR1. In addition, CBR1 expression status was correlated with the N classification (P<0.0001), stage (P=0.0018) and outcome (P=0.0095). Furthermore, a statistical correlation was determined between the protein expression status and overall survival (P=0.0171). In vitro studies indicated that the suppression of CBR1 by CBR1‑siRNA increased cancer cell proliferative, wound healing and migratory abilities. These findings suggest that low expression levels of CBR1 may affect cancer prognosis, and that CBR1 may have potential as a prognostic factor for patients with OSCC.

View Figures

View References

1	http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2014_jp.htmlCancer statistics in Japan-2014. March 14–2016
2	National Comprehensive Cancer Network, . NCCN clinical practice guidelines in oncology: Head and neck cancers. Version 1. 2012.http://www.nccn.org/clinical.aspMarch 14–2016
3	Inagi K, Takahashi H, Okamoto MA, Nakayama M, Makoshi T and Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Oto-Laryngol. 122:25–29. 2002. View Article : Google Scholar
4	Penning TM and Drury JE: Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys. 464:241–250. 2007. View Article : Google Scholar : PubMed/NCBI
5	Mindnich RD and Pennning TM: Aldo-Keto Reductase (Akr) superfamily: Genomics and annotation. Hum Genomics. 3:362–370. 2009.PubMed/NCBI
6	Miura T, Nishinaka T and Terada T: Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 315:113–121. 2008. View Article : Google Scholar : PubMed/NCBI
7	Gonzales-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L and Blanco JG: A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos. 35:973–980. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ismail E, Al-Mulla F, Tsuchida S, Suto K, Motley P, Harrison PR and Birnie GD: Carbonyl reductase: A novel metastasis-modulating function. Cancer Res. 60:1173–1176. 2000.PubMed/NCBI
9	Murakami A, Fukushima C, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Ismail E, Al-Mulla F and Sugino N: Suppression of carbonyl reductase expression enhances malignant behaviour in uterine cervical squamous cell carcinoma: Carbonyl reductase predicts prognosis and lymph node metastasis. Cancer Lett. 311:77–84. 2011. View Article : Google Scholar : PubMed/NCBI
10	Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F and Saito Y: Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Brit J Cancer. 85:1032–1036. 2001. View Article : Google Scholar : PubMed/NCBI
11	Leslie SH and Christian W: TNM Classification of Malignant Tumours. 6th. International union against cancer (UICC). Wiley-Blackwell; pp. 2642002
12	Pindborg JJ, Reichart PA, Smith CJ and van der Waal I: Histological typing of cancer and precancer of the oral mucosa. 2nd. World health organization (WHO). Springer-verlag; pp. 871997
13	Murakami A, Yakabe K, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Al-Mulla F and Sugino N: Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance. Cancer Lett. 323:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
14	Harada K, Ferdous T and Ueyama Y: Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol. 44:1302–1308. 2014. View Article : Google Scholar : PubMed/NCBI
15	Osawa Y, Yokoyama Y, Shigeto T, Futagami M and Mizunuma H: Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation. Int J Oncol. 46:1252–1258. 2015. View Article : Google Scholar : PubMed/NCBI
16	Cervical Cancer Treatment (PDQ®)-Health Professional Version, . National Cancer Institute. https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq#section/August 31–2016
17	Miura R, Yokoyama Y, Shigeto T, Futagami M and Mizunuma H: Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling. Int J Oncol. 47:2173–2180. 2015. View Article : Google Scholar : PubMed/NCBI
18	Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K and Birchmeier W: E-cadherin expression in squamous cell carcinomas of head and neck: Inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. 51:6328–6337. 1991.PubMed/NCBI
19	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
20	Momose F, Araida T, Negishi A, Ichijo H, Shioda S and Sasaki S: Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med. 18:391–395. 1989. View Article : Google Scholar : PubMed/NCBI
21	Takahashi H, Shigeta T, Umeda M and Komori T: A new in vitro invasion model for oral cancer using an acellular allogenic dermal matrix (Alloderm): The relationship among in vitro invasion activity, in vivo invasion and metastasis. Kobe J Med Sci. 57:E128–E136. 2012.PubMed/NCBI